Sobi and Apellis Pharmaceuticals, Inc. have announced encouraging one-year outcomes from the phase 2 NOBLE study, investigating the efficacy of systemic pegcetacoplan for treating post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). These findings were presented at the European Renal Association (ERA) Congress, held from May 23-26 in Stockholm, Sweden. […]
Apellis Pharmaceuticals said that it is on track to submit a new drug application (NDA) for its intravitreal pegcetacoplan to the US Food and Drug Administration (FDA) in the first half of 2022. The US-based biopharma company said that np further studies are required for the submission of the NDA for seeking approval for the […]
Apellis Pharmaceuticals has reported positive results for pegcetacoplan from the phase 2 DISCOVERY clinical trial in patients with C3 glomerulopathy (C3G), a type of kidney disease. According to the US biopharma company, the 48-week results demonstrated that patients subjected to pegcetacoplan had sustained improvements across key clinical measures. These include a greater than 65% mean […]
